Stock comparison
Genmab A/S
BeOne Medicines
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
ONC
BeOne Medicines
Market cap
$33.15B
Sector
Healthcare
Overall winner
BeOne Medicines ONC
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | ONC | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 62D | GMAB |
| Benjamin Graham | 64C | 75D | ONC |
| Philip Fisher | 48D | 84C | ONC |
| Peter Lynch | 25F | 75B | ONC |
| Joel Greenblatt | 76B | 49D | GMAB |
| Charlie Munger | 68C | 56D | GMAB |
| Terry Smith | 71C | 60D | GMAB |
Side-by-side metrics
| Metric | GMAB | ONC |
|---|---|---|
| Market cap | $16.5B | $33.15B |
| P/E (TTM) | 6.2x | 107.5x |
| EV/EBIT | 12.0x | 28.9x |
| ROIC (TTM) | 43.78% | 7.73% |
| Gross margin | 93.88% | 87.17% |
| Net margin | 18.23% | 8.93% |
| Revenue CAGR 5y | -18.45% | 45.99% |
| EPS CAGR 5y | -23.48% | 67.36% |
| Debt / Equity | 0.1x | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 107.5x+94%
- Debt / Equity0.1xvs 0.4x+83%
- ROIC (TTM)43.78%vs 7.73%+82%
- EV/EBIT12.0xvs 28.9x+59%
ONC leads on
- Revenue CAGR 5y45.99%vs -18.45%+140%
- EPS CAGR 5y67.36%vs -23.48%+135%
- Market cap$33.15Bvs $16.5B+50%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.